Carol D. Morris - Concepedia

Author

Carol D. Morris

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

C. D. E. Morris, C. D. Morris, C. Morris, C.D. Morris, CAROL D. MORRIS, CAVALIERI, Vincenzo, Carol D Morris, Carol D. Morris, Carol Morris, Morris, Carol D.

248

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Johns Hopkins University Johns Hopkins Medicine Cornell University Sidney Kimmel Comprehensive Cancer Center

About

Carol D. Morris is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, surgery, and orthopaedics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	29	1.4K
2	Engineering	5	5	125
3	Health Sciences	5	5	143
4	Biomedical Engineering	3	3	80
5	Public Health	1	1	11

Carol D. Morris

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan, Journal of Clinical Oncology	2015	412
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment Jeremy Whelan, Stefan Bielack, Neyssa Marina, Annals of Oncology	2014	321
NCCN Guidelines Insights: Bone Cancer, Version 2.2017 J. Sybil Biermann, Warren Chow, Damon R. Reed, Journal of the National Comprehensive Cancer Network Bone DiseaseMedicineCancer ManagementNccn Guidelines InsightsBone Cancer	2017	291
Survival in Patients Operated on for Pathologic Fracture: Implications for End-of-Life Orthopedic Care Saminathan S. Nathan, John H. Healey, Danilo Mellano, Journal of Clinical Oncology	2005	212
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma Paul A. Meyers, John H. Healey, Alexander J. Chou, Cancer	2010	176
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group Douglas S. Hawkins, Yueh-Yun Chi, James R. Anderson, Journal of Clinical Oncology	2018	170
Endoprosthetic Treatment is More Durable for Pathologic Proximal Femur Fractures Matthew R. Steensma, Patrick J. Boland, Carol D. Morris, Clinical Orthopaedics and Related Research	2011	161
Allograft-Prosthesis Composite Reconstruction of the Proximal Part of the Humerus Ayesha Abdeen, Bang H. Hoang, Edward A. Athanasian, Journal of Bone and Joint Surgery	2009	139
Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors Emanuela Palmerini, Eric L. Staals, Robert G. Maki, European Journal of Cancer Villonodular SynovitisSurgical PathologyImmunologyKinase InhibitorsPathology	2014	136
Bone Cancer J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Journal of the National Comprehensive Cancer Network Surgical OncologyBone CancersMedicineGiant Cell TumorPrimary Bone Cancers	2013	125

Page 1